102 Identification and preclinical characterization of NMS-P626, a potent, selective and orally bioavailable TrkA inhibitor with anti-tumor activity in a TrkA-dependent colorectal cancer
Elena Ardini(Nerviano Medical Sciences), Arturo Galvani(Nerviano Medical Sciences), Cristina Ponti(University of Milan), Dario Ballinari(Nerviano Medical Sciences), Paola Magnaghi(Nerviano Medical Sciences), Antonella Isacchi(Nerviano Medical Sciences), Maria Beatrice Saccardo(Nerviano Medical Sciences), Enrico Pesenti, Andrea Borgia(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia)
Cited by 6
Related Papers
Discovery of drug mode of action and drug repositioning from transcriptional responses
|Proceedings of the National Academy of Sciences|2010|853
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
NK Cells and Cancer
|The Journal of Immunology|2007|296
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205